(Q34174207)

English

Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

7

object named as

Stefan Zeuzem

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

author name string

Jane Scott

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Kathleen Rosa

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Min Fu

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Karin Cerri

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Monika Peeters

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Maria Beumont

6

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Donna M Evon

8

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Leen Gilles

9

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

publication date

26 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

BMC Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

14

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

465

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Validation of the Fatigue Severity Scale in chronic hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4162924

5 July 2018

Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4162924

5 July 2018

Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naïve genotype 1 hepatitis C: the randomized PILLAR study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4162924

5 July 2018

Review of patient-reported outcome measures in chronic hepatitis C

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4162924

5 July 2018

Fatigue before, during and after antiviral therapy of chronic hepatitis C: results from the Virahep-C study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4162924

5 July 2018

Hepatitis C therapy update

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4162924

5 July 2018

A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4162924

5 July 2018

Direct acting antivirals for the treatment of chronic hepatitis C: one pill a day for tomorrow

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4162924

5 July 2018

Boceprevir for previously treated chronic HCV genotype 1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4162924

5 July 2018

Boceprevir for untreated chronic HCV genotype 1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4162924

5 July 2018

Mapping onto Eq-5 D for patients in poor health

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4162924

5 July 2018

Fatigue rating scales critique and recommendations by the Movement Disorders Society task force on rating scales for Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4162924

5 July 2018

Future directions for investigation of fatigue in chronic hepatitis C viral infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4162924

5 July 2018

Living with hepatitis C: qualitative interviews with hepatitis C-infected veterans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4162924

5 July 2018

Emerging evidence of hepatitis C virus neuroinvasion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4162924

5 July 2018

Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4162924

5 July 2018

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4162924

5 July 2018

Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4162924

5 July 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4162924

5 July 2018

EQ-5D: a measure of health status from the EuroQol Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4162924

5 July 2018

Fatigue in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-465

21 January 2018

Fatigue and health-related quality of life (HRQL) in chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-465

21 January 2018

Fatigue and psychological disorders in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-465

21 January 2018

Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-465

21 January 2018

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-465

21 January 2018

The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-465

21 January 2018

Validation of the Turkish version of the fatigue severity scale in patients with fibromyalgia

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-465

21 January 2018

Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1186%2F1471-2334-14-465

21 January 2018

Living with chronic hepatitis C means 'you just haven't got a normal life any more'.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4162924

28 October 2018

Psychometric evaluation of the fatigue severity scale for use in chronic hepatitis C

1 reference

https://pubmed.ncbi.nlm.nih.gov/25164700

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Assessment of fatigue in patients with chronic hepatitis C using the Fatigue Impact Scale

1 reference

https://pubmed.ncbi.nlm.nih.gov/25164700

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus

1 reference

https://pubmed.ncbi.nlm.nih.gov/25164700

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2334-14-465

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34174207&oldid=2196347663"